{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-178827","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2024-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.852037+00:00","generated_at":"2026-05-31T20:42:37.442016+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pulse Biosciences enters $60M ATM equity facility; prelim Q2 net loss $10.7-12.7M","bullets":["Up to $60M at-the-market offering via Canaccord Genuity and Needham; commission up to 3%.","Preliminary Q2 2024 cash and cash equivalents $26.0-26.5M (excl. $60M rights offering close in July).","GAAP net loss $10.7-12.7M; non-GAAP net loss $8.7-9.7M.","GAAP costs and expenses $11-13M; non-GAAP costs $9-10M; adjustments include stock-based comp and D&A."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-178827","json":"https://secwatch.observer/filing/0001193125-24-178827.json","markdown":"https://secwatch.observer/filing/0001193125-24-178827.md","text":"https://secwatch.observer/filing/0001193125-24-178827.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000119312524178827/0001193125-24-178827-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000119312524178827/d867904d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:42:37.442016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}